Advanced Medical Solutions Group (CHIX:AMSL) Altman Z2-Score: 5.41 (As of Jun. 26, 2026) — 50% Below Median


CHIX:AMSL Advanced Medical Solutions Group PLC CHIX:AMSL
93 GF Score
Price £2.78
GF Value £3.71
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Advanced Medical Solutions Group Altman Z2-Score?

Advanced Medical Solutions Group CHIX:AMSL +14.17% 93 Altman Z2-Score is 5.41 as of Jun. 26, 2026, which is 50% below its 10-year median of 10.85. GuruFocus rates CHIX:AMSL with a GF Score™ of 93/100 and a GF Value™ of £3.71 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 845 Medical Devices & Instruments companies, Advanced Medical Solutions Group ranks better than 64.26% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Advanced Medical Solutions Group has a Altman Z2-Score of 5.41, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Advanced Medical Solutions Group's Altman Z2-Score or its related term are showing as below:

CHIX:AMSl' s Altman Z2-Score Range Over the Past 10 Years
Min: 4.85   Med: 10.85   Max: 12.13
Current: 5.41

During the past 13 years, Advanced Medical Solutions Group's highest Altman Z2-Score was 12.13. The lowest was 4.85. And the median was 10.85.


Advanced Medical Solutions Group  (CHIX:AMSl) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Advanced Medical Solutions Group Altman Z2-Score Related Terms


Advanced Medical Solutions Group Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Advanced Medical Solutions Group's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Medical Solutions Group Altman Z2-Score Chart

Advanced Medical Solutions Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.22 10.71 10.50 4.85 5.41

Advanced Medical Solutions Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.50 0.00 4.85 0.00 5.41

CHIX:AMSL vs ISRG, BDX, MDLN: Altman Z2-Score Comparison

For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Medical Solutions Group Altman Z2-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Advanced Medical Solutions Group's Altman Z2-Score falls into.


CHIX:AMSL
93GF Score
Advanced Medical Solutions Group PLC CHIX:AMSL
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advanced Medical Solutions Group Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Advanced Medical Solutions Group's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.2265+3.26*0.4677+6.72*0.0572+1.05*1.9217
=5.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2025:
Total Assets was £394.8 Mil.
Total Current Assets was £139.4 Mil.
Total Current Liabilities was £49.9 Mil.
Retained Earnings was £184.6 Mil.
Pre-Tax Income was £17.8 Mil.
Interest Expense was £-4.8 Mil.
Total Liabilities was £134.7 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(139.365 - 49.946)/394.77
=0.2265

X2=Retained Earnings/Total Assets
=184.637/394.77
=0.4677

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(17.783 - -4.803)/394.77
=0.0572

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(258.791 - 0)/134.666
=1.9217

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Advanced Medical Solutions Group has a Altman Z2-Score of 5.41 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 5.41 mean?
Advanced Medical Solutions Group (CHIX:AMSL) has a Altman Z2-Score of 5.41 as of Jun. 26, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Advanced Medical Solutions Group and its competitors. This is 50% below median its historical median of 10.85. Over the past decade, Advanced Medical Solutions Group's Altman Z2-Score has ranged from 4.85 to 12.13. According to the industry distribution chart, Advanced Medical Solutions Group ranks #302 out of 845 companies in the Medical Devices & Instruments industry, placing it in the top 35.7%.
Is Advanced Medical Solutions Group's Altman Z2-Score too high?
Advanced Medical Solutions Group's current Altman Z2-Score of 5.41 is 50% below median its 10-year median of 10.85. Over the past 10 years, this metric has ranged from a low of 4.85 to a high of 12.13. The Medical Devices & Instruments industry median Altman Z2-Score is 3.48. Advanced Medical Solutions Group's value of 5.41 is 55.5% above this industry median. Based on the distribution chart, Advanced Medical Solutions Group ranks #302 out of 845 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Advanced Medical Solutions Group has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's Altman Z2-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Advanced Medical Solutions Group ranks #302 out of 845 companies for Altman Z2-Score. This puts Advanced Medical Solutions Group in the upper half of its industry. The industry median Altman Z2-Score is 3.48. Advanced Medical Solutions Group's value of 5.41 is 55.5% above this benchmark. Historically, Advanced Medical Solutions Group's own Altman Z2-Score has ranged from 4.85 to 12.13 over the past decade. While the company's 10-year median is 10.85 vs. the industry median of 3.48, Advanced Medical Solutions Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Devices & Instruments company?
The median Altman Z2-Score among Medical Devices & Instruments companies is 3.48, based on 845 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Medical Solutions Group's current Altman Z2-Score of 5.41 is 55.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Advanced Medical Solutions Group and its competitors. For the Medical Devices & Instruments industry, the median Altman Z2-Score is 3.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Medical Solutions Group's current Altman Z2-Score is 5.41, which is 50% below median its own 10-year median of 10.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (CHIX:AMSL) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.71, compared to a current price of £2.78 — trading 25.1% below its estimated fair value. The current Altman Z2-Score is 5.41, which is 50% below median its 10-year median of 10.85 and 55.5% above the Medical Devices & Instruments industry median of 3.48. Advanced Medical Solutions Group's overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Advanced Medical Solutions Group (CHIX:AMSL), the current Altman Z2-Score is 5.41 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Advanced Medical Solutions Group (CHIX:AMSL) Overvalued in 2026?

Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued. The current stock price of £2.78 is trading 25.1% below its estimated GF Value™ of £3.71. GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.

Key valuation signals for CHIX:AMSL:

  • Altman Z2-Score: 5.41 (50% below median its 10-year median of 10.85)
  • GF Value™: £3.71 vs. price of £2.78 (25.1% below fair value)
  • GF Score™: 93/100 with 6 warning signs
  • Industry Position: 55.5% above the Medical Devices & Instruments median (#302 of 845)

No single metric tells the full story. See the CHIX:AMSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Advanced Medical Solutions Group Business Description

Other Exchanges AMS:UKAQA:Germany
Address Premier Park, 33 Road One, Winsford Industrial Estate, Winsford, Cheshire, GBR, CW7 3RT
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
93GF Score

Get the complete analysis for CHIX:AMSL

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£2.78
Price
£3.71
GF Value